Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

345 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland.
McSorley LM, Tharmabala M, Al Rahbi F, McSorley K, Chew S, Evoy D, Geraghty JG, Prichard RS, Rothwell J, McCartan DP, McDermott EW, Keane M, Kennedy MJ, O'Reilly S, Millen SJ, Crown JP, Smyth LM, Kelly CM, Quinn CM, Walshe JM. McSorley LM, et al. Among authors: kelly cm. Breast Cancer Res Treat. 2021 Aug;188(3):789-798. doi: 10.1007/s10549-021-06211-w. Epub 2021 Apr 9. Breast Cancer Res Treat. 2021. PMID: 33835293
Screen-detected ductal carcinoma in situ, 2008-2020: An observational study.
Kelly C, Fitzpatrick P, Quinn C, Flanagan F, Connors A, Larke A, Mooney T, Kennedy M, Sheehan M, Bennett MW, Brodie C, O'Doherty A. Kelly C, et al. J Med Screen. 2022 Sep;29(3):172-177. doi: 10.1177/09691413221090739. Epub 2022 Mar 28. J Med Screen. 2022. PMID: 35341364
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A. de Azambuja E, et al. Among authors: kelly cm. ESMO Open. 2024 Nov;9(11):103938. doi: 10.1016/j.esmoop.2024.103938. Epub 2024 Oct 17. ESMO Open. 2024. PMID: 39418883 Free PMC article. Clinical Trial.
Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma.
Movva S, Seier K, Avutu V, Banks LB, Chan J, Chi P, Dickson MA, Gounder MM, Kelly CM, Keohan ML, Maki R, Rosenbaum E, Salcito T, Rodriguez K, Dempsey R, Meyers PA, Cohen SM, Hensley ML, Konner JA, Schram AM, Lefkowitz RA, Erinjeri JP, Qin LX, Tap WD, D'Angelo SP. Movva S, et al. Among authors: kelly cm. Clin Cancer Res. 2024 Oct 15. doi: 10.1158/1078-0432.CCR-24-2519. Online ahead of print. Clin Cancer Res. 2024. PMID: 39405335
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.
Browne IM, McLaughlin RA, Weadick CS, O'Sullivan S, McSorley LM, Hadi DK, Millen SJ, Higgins MJ, Crown JP, Prichard RS, McCartan DP, Hill AD, Connolly RM, Noonan SA, O'Mahony D, Murray C, O'Hanlon-Brown C, Hennessy BT, Quinn CM, Kelly CM, O'Reilly S, Morris PG, Walshe JM. Browne IM, et al. Among authors: kelly cm. Breast Cancer Res Treat. 2024 Oct 4. doi: 10.1007/s10549-024-07486-5. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39365509
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Dugo M, et al. Among authors: kelly cm. Clin Cancer Res. 2024 Nov 1;30(21):4900-4909. doi: 10.1158/1078-0432.CCR-24-0149. Clin Cancer Res. 2024. PMID: 39308141 Free PMC article. Clinical Trial.
345 results